This study evaluated the efficacy and toxicity of immune checkpoint inhibitors in patients 70 and older with advanced NSCLC seen in routine clinical practice.
Journal of the American Geriatrics Society
Original Article: Immune Checkpoint Inhibitors in Older Adults With NSCLC